Publications
Genetic association analysis under complex survey sampling: the Hispanic Community Health Study/Study of Latinos." Am J Hum Genet 95, no. 6 (2014): 675-88.
"A global logrank test for adaptive treatment strategies based on observational studies." Stat Med 33, no. 5 (2014): 760-71.
"Joint modeling of longitudinal and survival data with missing and left-censored time-varying covariates." Stat Med 33, no. 26 (2014): 4560-76.
"Joint modeling of longitudinal and survival data with missing and left-censored time-varying covariates." Stat Med 33, no. 26 (2014): 4560-76.
"Meta-analysis of sequencing studies with heterogeneous genetic associations." Genet Epidemiol 38, no. 5 (2014): 389-401.
"Meta-analysis of sequencing studies with heterogeneous genetic associations." Genet Epidemiol 38, no. 5 (2014): 389-401.
"Meta-analysis of sequencing studies with heterogeneous genetic associations." Genet Epidemiol 38, no. 5 (2014): 389-401.
"More insights into early brain development through statistical analyses of eigen-structural elements of diffusion tensor imaging using multivariate adaptive regression splines." Brain Struct Funct 219, no. 2 (2014): 551-69.
"A multiple imputation method for sensitivity analyses of time-to-event data with possibly informative censoring." J Biopharm Stat 24, no. 2 (2014): 229-53.
"Multivariate longitudinal shape analysis of human lateral ventricles during the first twenty-four months of life." PLoS One 9, no. 9 (2014): e108306.
"Multivariate longitudinal shape analysis of human lateral ventricles during the first twenty-four months of life." PLoS One 9, no. 9 (2014): e108306.
"Multivariate recurrent events in the presence of multivariate informative censoring with applications to bleeding and transfusion events in myelodysplastic syndrome." J Biopharm Stat 24, no. 2 (2014): 429-42.
"Partial correlation matrix estimation using ridge penalty followed by thresholding and re-estimation." Biometrics 70, no. 3 (2014): 765-73.
"Partial correlation matrix estimation using ridge penalty followed by thresholding and re-estimation." Biometrics 70, no. 3 (2014): 765-73.
"Pathway-guided identification of gene-gene interactions." Ann Hum Genet 78, no. 6 (2014): 478-91.
"Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test." Stat Med 33, no. 12 (2014): 2004-16.
"Probability-enhanced sufficient dimension reduction for binary classification." Biometrics 70, no. 3 (2014): 546-55.
"Randomized phase II clinical trials." J Biopharm Stat 24, no. 4 (2014): 802-16.
"Sample size/power calculation for stratified case-cohort design." Stat Med 33, no. 23 (2014): 3973-85.
"Sample size/power calculation for stratified case-cohort design." Stat Med 33, no. 23 (2014): 3973-85.
"Sample size/power calculation for stratified case-cohort design." Stat Med 33, no. 23 (2014): 3973-85.
"Set-valued dynamic treatment regimes for competing outcomes." Biometrics 70, no. 1 (2014): 53-61.
"Set-valued dynamic treatment regimes for competing outcomes." Biometrics 70, no. 1 (2014): 53-61.
"SGPP: spatial Gaussian predictive process models for neuroimaging data." Neuroimage 89 (2014): 70-80.
"Stratified Fisher's exact test and its sample size calculation." Biom J 56, no. 1 (2014): 129-40.
"A trivariate meta-analysis of diagnostic studies accounting for prevalence and non-evaluable subjects: re-evaluation of the meta-analysis of coronary CT angiography studies." BMC Med Res Methodol 14 (2014): 128.
"Use of historical control data for assessing treatment effects in clinical trials." Pharm Stat 13, no. 1 (2014): 41-54.
"Assessing the causal effect of organ transplantation on the distribution of residual lifetime." Biometrics 69, no. 4 (2013): 820-9.
"Bayesian inference for multivariate meta-analysis Box-Cox transformation models for individual patient data with applications to evaluation of cholesterol-lowering drugs." Stat Med 32, no. 23 (2013): 3972-90.
"Bayesian inference for multivariate meta-analysis Box-Cox transformation models for individual patient data with applications to evaluation of cholesterol-lowering drugs." Stat Med 32, no. 23 (2013): 3972-90.
"Bayesian inference for multivariate meta-analysis Box-Cox transformation models for individual patient data with applications to evaluation of cholesterol-lowering drugs." Stat Med 32, no. 23 (2013): 3972-90.
"Bayesian modeling and inference for clinical trials with partial retrieved data following dropout." Stat Med 32, no. 24 (2013): 4180-95.
"Bayesian spatial transformation models with applications in neuroimaging data." Biometrics 69, no. 4 (2013): 1074-83.
"Bayesian spatial transformation models with applications in neuroimaging data." Biometrics 69, no. 4 (2013): 1074-83.
"Biclustering with heterogeneous variance." Proc Natl Acad Sci U S A 110, no. 30 (2013): 12253-8.
"Block-diagonal discriminant analysis and its bias-corrected rules." Stat Appl Genet Mol Biol 12, no. 3 (2013): 347-59.
"Block-diagonal discriminant analysis and its bias-corrected rules." Stat Appl Genet Mol Biol 12, no. 3 (2013): 347-59.
"Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION)." Am Heart J 165, no. 2 (2013): 193-9.
"Doubly-robust estimators of treatment-specific survival distributions in observational studies with stratified sampling." Biometrics 69, no. 4 (2013): 830-9.
"Efficient estimation of the distribution of time to composite endpoint when some endpoints are only partially observed." Lifetime Data Anal 19, no. 4 (2013): 513-46.
"Efficient estimation of the distribution of time to composite endpoint when some endpoints are only partially observed." Lifetime Data Anal 19, no. 4 (2013): 513-46.
"Empirical pathway analysis, without permutation." Biostatistics 14, no. 3 (2013): 573-85.
"Factor selection and structural identification in the interaction ANOVA model." Biometrics 69, no. 1 (2013): 70-9.
"A general framework for association tests with multivariate traits in large-scale genomics studies." Genet Epidemiol 37, no. 8 (2013): 759-67.
"A general framework for association tests with multivariate traits in large-scale genomics studies." Genet Epidemiol 37, no. 8 (2013): 759-67.
"Inference for optimal dynamic treatment regimes using an adaptive m-out-of-n bootstrap scheme." Biometrics 69, no. 3 (2013): 714-23.
"Inference for optimal dynamic treatment regimes using an adaptive m-out-of-n bootstrap scheme." Biometrics 69, no. 3 (2013): 714-23.
"Kappa statistic for clustered dichotomous responses from physicians and patients." Stat Med 32, no. 21 (2013): 3700-19.
"Kappa statistic for clustered dichotomous responses from physicians and patients." Stat Med 32, no. 21 (2013): 3700-19.
"Kappa statistic for clustered dichotomous responses from physicians and patients." Stat Med 32, no. 21 (2013): 3700-19.
"Localized differences in caudate and hippocampal shape are associated with schizophrenia but not antipsychotic type." Psychiatry Res 211, no. 1 (2013): 1-10.
"A longitudinal functional analysis framework for analysis of white matter tract statistics." Inf Process Med Imaging 23 (2013): 220-31.
"Marginal additive hazards model for case-cohort studies with multiple disease outcomes: an application to the Atherosclerosis Risk in Communities (ARIC) study." Biostatistics 14, no. 1 (2013): 28-41.
"Marginal additive hazards model for case-cohort studies with multiple disease outcomes: an application to the Atherosclerosis Risk in Communities (ARIC) study." Biostatistics 14, no. 1 (2013): 28-41.
"Marginal additive hazards model for case-cohort studies with multiple disease outcomes: an application to the Atherosclerosis Risk in Communities (ARIC) study." Biostatistics 14, no. 1 (2013): 28-41.
"Marginal additive hazards model for case-cohort studies with multiple disease outcomes: an application to the Atherosclerosis Risk in Communities (ARIC) study." Biostatistics 14, no. 1 (2013): 28-41.
"Marginal additive hazards model for case-cohort studies with multiple disease outcomes: an application to the Atherosclerosis Risk in Communities (ARIC) study." Biostatistics 14, no. 1 (2013): 28-41.
"Marginal additive hazards model for case-cohort studies with multiple disease outcomes: an application to the Atherosclerosis Risk in Communities (ARIC) study." Biostatistics 14, no. 1 (2013): 28-41.
"Medical records-based postmarketing safety evaluation of rare events with uncertain status." J Biopharm Stat 23, no. 4 (2013): 744-55.
"Meta-analysis of gene-level associations for rare variants based on single-variant statistics." Am J Hum Genet 93, no. 2 (2013): 236-48.
"Multicategory reclassification statistics for assessing improvements in diagnostic accuracy." Biostatistics 14, no. 2 (2013): 382-94.
"Multiscale adaptive generalized estimating equations for longitudinal neuroimaging data." Neuroimage 72 (2013): 91-105.
"Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity." Pharmacogenomics 14, no. 2 (2013): 205-13.
"ROC curve estimation under test-result-dependent sampling." Biostatistics 14, no. 1 (2013): 160-72.
"ROC curve estimation under test-result-dependent sampling." Biostatistics 14, no. 1 (2013): 160-72.
"ROC curve estimation under test-result-dependent sampling." Biostatistics 14, no. 1 (2013): 160-72.
"ROC curve estimation under test-result-dependent sampling." Biostatistics 14, no. 1 (2013): 160-72.
"ROC curve estimation under test-result-dependent sampling." Biostatistics 14, no. 1 (2013): 160-72.
"ROC curve estimation under test-result-dependent sampling." Biostatistics 14, no. 1 (2013): 160-72.
"Sample size considerations of prediction-validation methods in high-dimensional data for survival outcomes." Genet Epidemiol 37, no. 3 (2013): 276-82.
"Sample size estimation in educational intervention trials with subgroup heterogeneity in only one arm." Stat Med 32, no. 12 (2013): 2140-54.
"Bayesian lasso for semiparametric structural equation models." Biometrics 68, no. 2 (2012): 567-77.
"Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes." Biometrics 68, no. 2 (2012): 578-86.
"Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes." Biometrics 68, no. 2 (2012): 578-86.
"Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes." Biometrics 68, no. 2 (2012): 578-86.
"Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes." Biometrics 68, no. 2 (2012): 578-86.
"Bayesian methods in clinical trials: a Bayesian analysis of ECOG trials E1684 and E1690." BMC Med Res Methodol 12 (2012): 183.
"Checking semiparametric transformation models with censored data." Biostatistics 13, no. 1 (2012): 18-31.
"Checking semiparametric transformation models with censored data." Biostatistics 13, no. 1 (2012): 18-31.
"Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer." J Natl Cancer Inst 104, no. 3 (2012): 211-27.
"Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer." J Natl Cancer Inst 104, no. 3 (2012): 211-27.
"Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer." J Natl Cancer Inst 104, no. 3 (2012): 211-27.
"Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer." J Natl Cancer Inst 104, no. 3 (2012): 211-27.
"Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer." J Natl Cancer Inst 104, no. 3 (2012): 211-27.
"Data for cancer comparative effectiveness research: past, present, and future potential." Cancer 118, no. 21 (2012): 5186-97.
"Data for cancer comparative effectiveness research: past, present, and future potential." Cancer 118, no. 21 (2012): 5186-97.
"A framework for understanding cancer comparative effectiveness research data needs." J Clin Epidemiol 65, no. 11 (2012): 1150-8.
"A framework for understanding cancer comparative effectiveness research data needs." J Clin Epidemiol 65, no. 11 (2012): 1150-8.
"Marginal hazard regression for correlated failure time data with auxiliary covariates." Lifetime Data Anal 18, no. 1 (2012): 116-38.
"Marginal hazard regression for correlated failure time data with auxiliary covariates." Lifetime Data Anal 18, no. 1 (2012): 116-38.
"Marginal hazard regression for correlated failure time data with auxiliary covariates." Lifetime Data Anal 18, no. 1 (2012): 116-38.
"Meta-analysis methods and models with applications in evaluation of cholesterol-lowering drugs." Stat Med 31, no. 28 (2012): 3597-616.
"Meta-analysis methods and models with applications in evaluation of cholesterol-lowering drugs." Stat Med 31, no. 28 (2012): 3597-616.
"Missing data in clinical studies: issues and methods." J Clin Oncol 30, no. 26 (2012): 3297-303.
"Multiscale adaptive marginal analysis of longitudinal neuroimaging data with time-varying covariates." Biometrics 68, no. 4 (2012): 1083-92.
"Multivariate phenotype association analysis by marker-set kernel machine regression." Genet Epidemiol 36, no. 7 (2012): 686-95.
"Multivariate phenotype association analysis by marker-set kernel machine regression." Genet Epidemiol 36, no. 7 (2012): 686-95.
"Network meta-analysis of margin threshold for women with ductal carcinoma in situ." J Natl Cancer Inst 104, no. 7 (2012): 507-16.
"Network meta-analysis of margin threshold for women with ductal carcinoma in situ." J Natl Cancer Inst 104, no. 7 (2012): 507-16.
"Phase II cancer clinical trials with heterogeneous patient populations." J Biopharm Stat 22, no. 2 (2012): 312-28.
"